NEWAMSTERDAM PHARMA COMPANY's ticker is and the CUSIP is N62509109.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $124,534,826 | 12.83% |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $34,119,128 | 9.56% |
| Frazier Life Sciences Management, L.P. | 10,871,803 | $129,265,738 | 7.72% |
| RA Capital Management | 9,000,000 | $107,010,000 | 2.02% |
| Eversept Partners, LP | 692,369 | $8,232,267 | 0.69% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,535,723 | $30,149,746 | 0.64% |
| GMT CAPITAL CORP | 1,383,800 | $16,453,382 | 0.62% |
| BVF INC/IL | 1,521,948 | $18,095,962 | 0.50% |
| Parkman Healthcare Partners LLC | 239,051 | $2,842,316 | 0.49% |
| Affinity Asset Advisors, LLC | 100,000 | $1,189,000 | 0.42% |